Why the study?
Does adjuvant recombinant interferon alfa-2b improve overall and event-free survival in patients with Robson stages II and III renal cell carcinoma after radical nephrectomy?
Does adjuvant recombinant interferon alfa-2b improve overall and event-free survival in patients with Robson stages II and III renal cell carcinoma after radical nephrectomy?
Adjuvant recombinant interferon alfa-2b does not improve overall or event-free survival after radical nephrectomy for Robson stages II and III renal cell carcinoma and is not indicated.
Answers are grounded in this paper and cite their sources.
Adjuvant interferon alfa-2b should not be used after nephrectomy for Robson II-III RCC; confirms no survival benefit in this RCT.
PURPOSE: Because interferon gave promising results in the management of metastatic renal cell carcinoma in the 1980s, a multicentric randomized controlled trial was planned to compare adjuvant recombinant interferon alfa-2b (rIFNalpha2b) with observation after radical nephrectomy in patients with Robson stages II and III renal cell carcinoma. Overall and event-free survival were to be evaluated together with prognostic factors. PATIENTS AND METHODS: Overall and event-free survival curves for 247 patients (124 controls and 123 treated) were estimated by the Kaplan-Meier method and compared using the log-rank test. Cox's multiple regression models were adopted to perform a joint analysis of treatment and prognostic factors. RESULTS: The 5-year overall and event-free survival probabilities were 0.665 and 0.671, respectively, for controls and 0.660 and 0.567, respectively, for the treated group; the differences were not statistically significant (2P = .861 for overall and 2P = .107 for event-free survival with the log-rank test). Regarding prognostic factors, only grade, pT, and pN demonstrated a significant prognostic role. First-order interactions of treatment with pT and pN category were investigated; a significant interaction was found between pN and treatment. A harmful effect of rIFNalpha2b in the 97 treated pN0 patients and a protective effect in the 13 treated pN2/pN3 patients were statistically significant. CONCLUSION: Adjuvant rIFNalpha2b is not indicated after radical nephrectomy for renal cell carcinoma. The protective effect in the small group of pN2/pN3 patients requires further investigation.
No takes yet. Share an insight, caveat, or question.
Pizzocaro et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: